Physician profile
Jamie E Taffora
NPI 1144238890
$2,165.45
in general payments reported to CMS, 2019-2025
26 companies · $513 in 2025
The $513 reported for 2025 was more than what 78% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $179 · 2020: $133 · 2021: $191 · 2022: $320 · 2023: $318 · 2024: $513 · 2025: $513.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,343.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,342.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $332.05 | 2022-2025 | Rocklatan, Hydrus Microstent, Eysuvis |
| Bausch & Lomb Americas INC. | $277.50 | 2022-2025 | Vyzulta, Miebo, Lotemax Sm |
| Sun Pharmaceutical Industries INC. | $183.82 | 2019-2025 | Cequa, Xelpros |
| Mallinckrodt Hospital Products INC. | $138.63 | 2024-2025 | Acthar |
| Tarsus Pharmaceuticals, INC. | $129.97 | 2024-2025 | Xdemvy |
| Kala Pharmaceuticals, INC. | $104.35 | 2019-2021 | |
| Dompe US, INC. | $102.71 | 2024-2025 | Oxervate |
| Harrow Eye, LLC | $98.77 | 2024-2025 | Vevye |
| Novartis Pharmaceuticals Corporation | $97.43 | 2019-2023 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $78.49 | 2019-2021 | |
| Allergan, INC. | $77.47 | 2019-2021 | |
| Abbvie INC. | $64.60 | 2022 | |
| Biotissue Holdings INC. | $57.56 | 2019-2023 | |
| Shire North American Group INC | $57.25 | 2019 | |
| Horizon Therapeutics Plc | $56.66 | 2021-2022 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Oyster Point Pharma, INC. | $52.36 | 2022 | |
| Amgen INC. | $45.18 | 2025 | Tepezza |
| Rayner Intraocular Lenses Limited | $33.83 | 2024 | Rayone Aspheric, Rayone Emv, Omidria |
| Astellas Pharma US INC | $31.21 | 2025 | Izervay |
| Ivantis, INC | $24.07 | 2020-2021 | |
| Thea Pharma INC. | $23.42 | 2023 | Iyuzeh |
| Aerie Pharmaceuticals, INC. | $22.35 | 2019 | |
| Sight Sciences, INC. | $22.13 | 2023 | Tearcare System |
| Glaukos Corporation | $20.93 | 2025 | Idosetr, Istent Inject W |
| Carl Zeiss Meditec, INC. | $17.24 | 2020 | |
| Merz Pharmaceuticals, LLC | $15.47 | 2025 | Xeomin |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jamie Taffora listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.